BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23085437)

  • 1. Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion.
    Griner SE; Joshi JP; Nahta R
    Biochem Pharmacol; 2013 Jan; 85(1):46-58. PubMed ID: 23085437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth Differentiation Factor 15 Promotes Progression of Esophageal Squamous Cell Carcinoma via TGF-β Type II Receptor Activation.
    Okamoto M; Koma YI; Kodama T; Nishio M; Shigeoka M; Yokozaki H
    Pathobiology; 2020; 87(2):100-113. PubMed ID: 31896114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3.
    Ghosh S; Basu M; Roy SS
    J Biol Chem; 2012 Apr; 287(18):15001-15. PubMed ID: 22270366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
    Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
    Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of ARK5 expression suppresses invasion of ovarian cancer cells.
    Wang S; Li S; Wang H; Li W; Gao Y; Wang X; Fang C; Zhang B; Sun X; Li R; Shi W; Chen M; Shi L
    Mol Med Rep; 2019 Apr; 19(4):2927-2934. PubMed ID: 30720082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
    Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
    Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2.
    Li S; Ma YM; Zheng PS; Zhang P
    J Exp Clin Cancer Res; 2018 Apr; 37(1):80. PubMed ID: 29636108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
    Joshi JP; Brown NE; Griner SE; Nahta R
    Biochem Pharmacol; 2011 Nov; 82(9):1090-9. PubMed ID: 21803025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression.
    Karam AK; Santiskulvong C; Fekete M; Zabih S; Eng C; Dorigo O
    Cytoskeleton (Hoboken); 2010 Aug; 67(8):535-44. PubMed ID: 20607860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells.
    Zhou HY; Wong AS
    Endocrinology; 2006 May; 147(5):2557-66. PubMed ID: 16469801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Ras homolog gene family, member C gene silencing combined with rapamycin on hepatocellular carcinoma cell growth.
    Xie SL; Zhu MG; Chen GF; Wang GY; Lv GY
    Mol Med Rep; 2015 Oct; 12(4):5077-85. PubMed ID: 26165487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twist promotes invasion and cisplatin resistance in pancreatic cancer cells through growth differentiation factor 15.
    Ji H; Lu HW; Li YM; Lu L; Wang JL; Zhang YF; Shang H
    Mol Med Rep; 2015 Sep; 12(3):3841-3848. PubMed ID: 26018318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfated polysaccharide of Sepiella Maindroni ink inhibits the migration, invasion and matrix metalloproteinase-2 expression through suppressing EGFR-mediated p38/MAPK and PI3K/Akt/mTOR signaling pathways in SKOV-3 cells.
    Jiang W; Cheng Y; Zhao N; Li L; Shi Y; Zong A; Wang F
    Int J Biol Macromol; 2018 Feb; 107(Pt A):349-362. PubMed ID: 28870748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
    Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
    Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway.
    Zhu H; Diao S; Lim V; Hu L; Hu J
    Acta Biochim Biophys Sin (Shanghai); 2019 May; 51(5):509-516. PubMed ID: 30939187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
    Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
    Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
    Thimmaiah KN; Easton J; Huang S; Veverka KA; Germain GS; Harwood FC; Houghton PJ
    Cancer Res; 2003 Jan; 63(2):364-74. PubMed ID: 12543789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GDF15 derived from both tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression via Akt and Erk pathways.
    Urakawa N; Utsunomiya S; Nishio M; Shigeoka M; Takase N; Arai N; Kakeji Y; Koma Y; Yokozaki H
    Lab Invest; 2015 May; 95(5):491-503. PubMed ID: 25730371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways.
    Chen Y; Zheng L; Liu J; Zhou Z; Cao X; Lv X; Chen F
    Int Immunopharmacol; 2014 Aug; 21(2):447-55. PubMed ID: 24905636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.